Market Newsdesk

BBTV Holdings Reports Record Revenues and Q3 2020 Results

Recent Highlights

• BBTV achieved record quarterly revenues of $120.7 Million, a 31% increase in revenues on a YoY basis, driven by growth in Views and improved ad sell through rates
• BBTV experienced an 18% increase in Views to 121.2 billion from 102.7 billion in Q3 2019 across various platforms such as YouTube, solidifying its global leadership among media-tech companies
• Raised $172.4 million in proceeds from share offering substantially subscribed to by leading financial institutions, enabling acquisition of operating business and cash to execute on growth strategies

VANCOUVER, British Columbia–(BUSINESS WIRE)–
BBTV Holdings Inc. (TSX: BBTV) (the “Company”), a media tech company that uses technology enabled solutions to help content owners become more successful, today announced the financial results for its operating business BroadbandTV Corp. for the three-month period ended September 30, 2020. All currency is in Canadian dollars unless otherwise noted.

“We are very pleased with our performance during Q3, as we executed on our strategy to increase our global scale and experienced strong growth in audience views of our content, accelerated by beneficial secular tailwinds including television viewers ‘cutting the cord’ to watch digital video on demand,” said Shahrzad Rafati, Chairperson, Founder and CEO of BBTV. “The global COVID-19 pandemic has accelerated the shift of consumption from mainstream media to digital media, and we are seeing advertisers follow these audiences online as digital advertising rebounded in the third quarter following a temporary slowdown in growth in Q2.”

“Following the quarter, we successfully completed our IPO and listed on the TSX. We are committed to executing on our growth strategies including investments in our technology, scaling and expanding our higher margin Plus Solutions as well as accretive strategic acquisitions to power our Base and Plus Solutions,” added Rafati. “The strong growth in digital content consumption such as short form videos means our unique solutions are in more demand than ever, as content owners need our platform expertise to help them increase views and improve revenue generation across the growing number of digital platforms while allowing them to focus on their core competency – content creation.”

In accordance with its recent initial public offering and acquisition of RTL’s share of the Company, which occurred subsequent to the close of its third quarter September 30, 2020, the Company is providing the results of operations of BroadbandTV Corp. only at this time. BBTV Holdings, is a holding company which acquired the RTL interest, but other than transaction related costs, it does not currently generate revenue, and operating expenses for the quarter are expected to be below $400,000, excluding IPO and RTL transaction related costs. The financial statements for the Company will be filed separately. A pro-forma for the period ended June 30, 2020, which combines the BroadbandTV Corp and BBTV Holdings entity post the transaction is included in the Prospectus. A pro-forma for the period ended Sept 30, 2020 will be filed at a later date.

Revenue for the three months ended September 30, 2020 (“Q3 2020”) increased by $28.3 million or 31% as compared to the three months ended September 30, 2019 (“Q3 2019”), primarily driven by our continued focus on acquiring content that is brand-safe with audiences in geographies with high RPMs¹ or high RPM¹ growth, as well as corresponding increases across existing Views and RPMs¹. Revenue for the nine months ended September 30, 2020 (“YTD 2020”) increased by $43.6 million or 16% as compared to the nine months ended September 30, 2019 (“YTD 2019”), primarily driven by the same factors impacting Q3 2020, partially offset by the negative impact on advertising spend, including digital advertising, in the second quarter of 2020 stemming from the COVID-19 pandemic which has subsequently rebounded.

Gross profit for Q3 2020 decreased by $0.4 million or 4% compared to Q3 2019. Gross profit for YTD 2020 decreased by $1.5 million or 6% compared to YTD 2019. The lower gross margin was primarily due to content mix, more specifically; 1) less advertising on kids content, 2) the impact of COVID-19 on Plus Solutions from less content being produced, and 3) the previous penetration pricing efforts². We expect gross margins to improve as some of the temporary effects related with COVID-19 wear off, as we expand our Plus Solutions, gain greater market share, and execute our accretive M&A strategy.

Although Plus Solutions were more heavily impacted by COVID-19, Plus Solutions revenue increased 27% from July to September during Q3 2020 and Direct Advertising Sales, in particular, is showing signs of recovery growing 55% from July to September. Additionally, we are entering our seasonal high revenue period, Q4. Accordingly, we are optimistic that Plus Solution revenue will return to higher growth in Q4 2020.

Adjusted EBITDA for Q3 2020 decreased by $0.8 million compared to Q3 2019. Adjusted EBITDA for YTD 2020 decreased by $4.2 million compared to YTD 2019. The higher loss for the current period was primarily due to the lower margins realized as per above, as well as some additional investments in operating expenses associated with Plus Solution initiatives.

Net Loss for Q3 2020 decreased by $0.8 million compared to Q3 2019. The net loss YTD 2020 was $11.5 million.

IPO Update and Financial Position

On Oct. 28, 2020, the Company completed its initial public offering, and raised approximately $172.4 million in gross proceeds through the issuance of 10,775,000 subordinate voting shares at $16 per share (the “Offering”), and currently has approximately 20.5 million shares outstanding on pro-forma basis. The Company utilized the net proceeds of the Offering to complete the acquisition of 100% of the issued and outstanding equity of BroadbandTV Corp. The Company intends that the remaining Offering proceeds will be used to pay for expenses related to the Offering, and to fund business operations, strategic acquisitions and growth initiatives. Immediately following completion of the Offering, the Company will have on a consolidated basis, approximately $10 million in cash and cash equivalents, after fees and expenses and $46 million in long term debt in the form of convertible notes.

Webcast and Conference Call Information

The Company will hold a conference call today at 1:00 pm EST hosted by Ms. Shahrzad Rafati, Chairperson and CEO, and Mr. Todd Tappin, Chief Financial Officer. Ms. Rafati and Mr. Tappin will review the Q3 results and discuss: 1- The Company’s over-arching growth strategy, 2- The Company’s continued resilience and strong performance during the COVID-19 pandemic and 3- the overall outlook for the business. A question and answer session will follow the corporate update.

All interested parties can join the call by dialing (647) 427-2311 or (866) 521-4909 and referencing BBTV Holdings Third Quarter Earnings Call, conference ID number 4798154. Please dial in 15 minutes prior to the call to secure a line. A live audio webcast of the conference call will also be available at investors.bbtv.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. A replay will be available shortly after the call for 21 days. To access the replay, please dial (800) 585-8367 or (416) 621-4642 and enter access code 4798154.

Footnotes:

1- “RPMs” or “Revenue per one thousand video Views” means the Advertising Revenue for every thousand video Views generated by the Company’s owned and licensed digital content. Advertising types include pre/mid/post-roll advertisements that run on the Company’s owned and licensed content across digital platforms. The Company does not provide a reconciliation for RPMs as there are no directly comparable IFRS measures for the components that make up RPMs.

2- Penetration pricing strategy means strategy employed to capture market share relating to prior periods for Base Solutions where contracts are one year long.

About BBTV

BBTV is a media and technology company headquartered in Vancouver, Canada that uses technology enabled solutions to help content owners become more successful. BBTV is an enabling platform with a stated mission of advancing the world through the democratization of content. From individual content creators to global media companies, BBTV monetizes the media of content owners through end-to-end management, distribution and monetization solutions, powered by its innovative VISO Platform, including related proprietary technology, while allowing content owners to focus on their core competency – content creation. In June 2020, BBTV had the second most unique monthly viewers among digital platforms with 596 million globally, who consumed more than 54 billion minutes of video content, the most among media companies³www.bbtv.com

3- Calculations and classifications made by BBTV based on data from Comscore contained in Comscore’s “Top 12 Countries = June 2020 comScore Video Metrix Media Trend – Multi-Platform – Top 100 Video Properties Report”.

Forward-Looking Statements

This press release contains forward‐looking information within the meaning of applicable securities legislation, including statements with regards to the timing of the release of the third quarter results and related conference call, the Company’s growth and capital markets objectives, and expectations regarding future results, including without limitation, revenue, margins and other financial results, which forward-looking information reflects the Company’s current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking information. Such risks and uncertainties include, but are not limited to, having to change anticipated timing of our release and conference call, failure to meet our growth or capital markets objectives, or achieve our expected results, or other future adverse events, and the factors discussed under “Risk Factors” in the final prospectus of the Company dated October 22, 2020. The Company does not undertake any obligation to update such forward‐looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Reconciliations of Non-IFRS Measures

Adjusted EBITDA and Adjusted EBITDA Margin

In thousands of Canadian Dollars (except percentages)	Three Months Ended September 30,			Nine Months Ended September 30,
	2020	2019		2020	2019
Net loss	($1,951)	($2,712)		($11,542)	($6,935)
Amortization and depreciation	$664	$730		$2,071	$2,020
Share-based compensation	$176	$21		$236	$100
Unrealized and realized foreign exchange	($958)	$796		$1,157	($200)
Interest expense	$985	$905		$2,926	$2,658
Other expense (income)	$291	($74)		$288	($248)
Receivable factoring banking fees	$116	$229		$416	$467
Transaction-related costs	$54	–		$69	$238
Provision for income taxes	($99)	$144		($155)	$1,528
Adjusted EBITDA	($722)	$39		($4,534)	($372)
Total revenues	$120,676	$92,405		$308,182	$264,561
Adjusted EBITDA Margin	(0.6%)	0.0%		(1.5%)	(0.1%)

BBTV-F

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005255/en/

For Further Information:

BBTV Holdings

Media:

Dan Gamble, Head of PR and Corporate Communications

[email protected]

+1778 873 0422

Investors:

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Other Technology General Entertainment Technology Entertainment TV and Radio

MEDIA:

Logo

Americas Gold and Silver Corporation Reports Third Quarter 2020 Results and Provides Operations Update

TORONTO–(BUSINESS WIRE)–
Americas Gold and Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas” or the “Company”), a growing North American precious metals producer, reports consolidated financial and operational results for the third quarter of 2020 along with an operations update.

This earnings release should be read in conjunction with the Company’s Management’s Discussion and Analysis, Financial Statements and Notes to Financial Statements for the corresponding period, which have been posted on the Americas Gold and Silver Corporation SEDAR profile at www.sedar.com, and on its EDGAR profile at www.sec.gov, and which are also available on the Company’s website at www.americas-gold.com. All figures are in U.S. dollars unless otherwise noted.

Operational and Third Quarter Financial Highlights

• Revenue of $7.3 million and a net loss of $6.2 million for Q3-2020 or a loss of ($0.05) per share
• Year-to-date operating metrics were largely unchanged in Q3-2020 from Q2-2020 due to the illegal blockade at the Cosalá Operations, suspension of operating metrics during the Galena Complex recapitalization plan (“Recapitalization Plan”), and ongoing pre-production at Relief Canyon
• Galena Complex silver production increased by 25% year-over-year while Galena lead production increased by 65%, benefitting from the Recapitalization Plan described in detail below
• At Relief Canyon, the radial stacker is expected to be installed and operating in the coming week. The Company anticipates the increase in production from the return of the radial stacker will allow the Company to declare commercial production by the end of Q4-2020
• Since placing ore on the 6W leach pad on August 4, 2020, ore leaching has performed within expected norms
• Benefits from the Galena Complex Recapitalization Plan are materializing including the significant increase to the mineral resources. Measured and indicated silver resource, as of June 30, 2020, increased by 36% to 37.3 million ounces¹ and inferred silver resource increased by over 100% to 78.6 million ounces¹. This is based on only 33% of Phase 1 planned drilling and further increases are expected as the drill program continues
• The Company finalized the option payment for the San Felipe project and paid the remaining $3.75 million plus VAT obligation in common shares of the Company on October 8, 2020. The San Felipe project is now 100% owned by the Company and contains an indicated silver resource of over 9 million ounces and an inferred silver resource of over 3 million ounces
• The Company had a cash balance of $22.8 million as at September 30, 2020

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

— ~$3.7 Million Clinical Grant to Fund U.S. Phase 1 Study of RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis —

NEW YORK–(BUSINESS WIRE)–
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $3.7 million CLIN2 grant award to support the clinical development of its lentiviral vector (LVV)-based gene therapy, RP-L401, for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder characterized by skeletal deformities, neurologic abnormalities and bone marrow failure. The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allowed $3 billion in state funding for stem cell research conducted in California. This will be Rocket’s second CIRM grant after receiving one in 2019 for the development of the company’s gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I).

“We’re grateful the CIRM has recognized the promise of RP-L401 for IMO, a devastating pediatric rare disease for which the primary treatment option is allogeneic bone marrow transplant,” said Jonathan Schwartz, M.D. Chief Medical Officer and Senior Vice President of Rocket. “RP-L401 could be a potentially curative treatment for this devastating disorder that affects children at a young age, and we are thankful to have this meaningful support from the CIRM to move our program forward for these families.”

Rocket’s Investigational New Drug Application (IND) for RP-L401 was accepted by the U.S. Food and Drug Administration (FDA) in June of 2020, and the gene therapy received Fast Track designation from the FDA in August 2020. Proceeds from the grant will help fund clinical trial costs, as well as provide manufactured drug product for Phase 1 patients enrolled at the U.S. clinical trial site, University of California, Los Angeles, led by principal investigator Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles. The non-randomized, open-label Phase 1 clinical trial will enroll two pediatric patients, one month of age or older. The trial is designed to assess safety and tolerability of RP-L401, as well as preliminary efficacy, including potential improvements in bone abnormalities/density, hematologic status and endocrine abnormalities. Further information about the clinical program is available here.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

RP-L401 was in-licensed from Lund University and Medizinische Hochschule Hannover. Rocket’s IMO research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-12095). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other agency of the State of California.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed November 6, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005176/en/

Claudine Prowse, Ph.D.

SVP, Strategy & Corporate Development

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Health Stem Cells Genetics Clinical Trials Pharmaceutical Cardiology Biotechnology

MEDIA:

Posted on November 13, 2020 7:03 am

Warrior Gold Announces Advisory Board Appointment and Provides Exploration and Corporate Update

Warrior Gold Announces Advisory Board Appointment and Provides Exploration and Corporate Update

TORONTO–(BUSINESS WIRE)–Warrior Gold Inc. (TSX-V – WAR) (“Warrior Gold” or the “Company”) ispleased to provide a corporate update including the immediate appointment of Linda Wrong, P.Geo., CSR-P, to the Company’s Advisory Board. Ms. Wrong is a Professional Geoscientist and Certified Sustainability Practitioner with over 25 years of international experience in the exploration and mining industry, beginning her career as an exploration geologist in the Kirkland Lake Area with Kerr Addison Mines. As former Vice President of Environment and Permitting at Labrador Iron Mines, Linda successfully led the team through the environmental assessment and permitting processes for the James Mine, obtaining the required permits which led to the start of operations within two years of submitting regulatory filings. Following Labrador Iron Mines, Linda assumed senior environmental and sustainability leadership positions at Barrick Gold, Hudbay Minerals, and Lundin Mining. Linda is currently the Global General Manager, Corporate Environment at Glencore International, leading environmental initiatives across their international operations.

Danièle Spethmann, President and CEO of Warrior Gold stated, “We are very pleased that Linda has joined the Warrior Gold team. Linda’s extensive geological and industry expertise across northern Canada, including the Kirkland Lake camp, as well as her familiarity with the provincial and federal Canadian environmental and permitting processes, will support the Company’s efforts to advance the Goodfish- Kirana project.”

Exploration Update

The Company is also pleased to provide an exploration update further to its press release of August 20^th announcing the initiation of a field mapping program and a collaborative advanced study program led by Dr. Neil Banerjee of Western University’s Department of Earth Sciences and Dr. Lisa Van Loon of LISA CAN Analytical Solutions. To date, 13 drill core samples and 84 pulps have been selected from the Goodfish-Kirana “A” and “C” Zones for a synchrotron mineral cluster analysis. The program will assess the link between alteration and mineralization from these zones, as well as the newly recognized mineralization (“A” Zone NS-FW) identified in the summer drill program. These samples will also be submitted for petrography, X-ray microscopy, and microprobe analysis to provide mineralogy of ore phases and gold textural information.

The Company is currently assessing all recently acquired drill data and additional analytical results (multi-element and screen-metallic) in conjunction with reprocessing historical raw geophysical data in advance of a drill-targeting exercise. In addition, the Company will be initiating an in-situ borehole survey test program consisting of (a) an Optical Televiewer (OTV) which collects a detailed high-resolution oriented image of the borehole wall that provides structural information such as the orientation of veins, lithological contacts, shear fabrics, etc., and (b) a Mineralization Logging Suite (MLS) survey comprised of Induced Polarization (IP), Resistivity and Natural Gamma. This work is expected to be completed by the end of November and will be used to validate previously collected structural data, capture structural information in domains where oriented drilling failed and provide a geophysical signature of mineralization which will aid in future geophysical program planning.

Infrastructure work includes renovating the Company’s new core logging facilities in the town of Kirkland Lake.

Corporate Update

On October 22, 2020, the Company held its Annual General and Special meeting of shareholders (the “Meeting”) which was shared online via Zoom. A total of 26,464,815 common shares of the Company were represented, approximately 33% of the total number of shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including the election of four management nominees to the board of directors, the appointment of Crowe MacKay LLP as auditors for the ensuing year, the authorizing of the directors to fix their remuneration, and the re-approval of the Company’s 10% stock option plan.

The Company also confirms the extension to the expiry date of 5,322,739 warrants. Further to the Company’s press release of September 23, 2020, the TSX Venture Exchange provided approval for the extension of time for exercise. The approved extension provides for 4,533,239 warrants that were originally scheduled to expire on September 25, 2020, to expire on March 25, 2020, and for 789,500 warrants originally scheduled to expire on November 20, 2020, to expire on May 20, 2021. The Company did not amend the exercise price of $0.15.

Warrior Gold also announces that the Company will be participating at the 121 Mining Investment EMEA virtual investment conference being held November 18^th through November 20^th. This event connects exploration and mining management teams with investors from institutional funds, private equity groups, family offices, and sector analysts via one-on-one, 30-minute video meetings. Danièle Spethmann, CEO and Melissa Render, Principal Consulting Geologist, will be participating in these meetings. The Company highlights that these sessions will be held live.

About Warrior Gold Inc.

Warrior Gold is a TSX Venture Exchange-listed Company that owns the Goodfish-Kirana Property located five km from the town of Kirkland Lake, Ontario. The Property is located in the historic Kirkland Lake Gold Camp which is situated in the prolific Abitibi Greenstone Belt, recognized as one of the world’s highest grade greenstone belts with over 200 million ounces of gold produced to date.

The Goodfish-Kirana Property is 11.5 km long by roughly three km wide (34 km²) and contains three major structural trends: the east-west trending Kirana Deformation Zone; the northeast-trending Goodfish Deformation Zone; and the Victoria Creek Deformation Zone on the recently acquired Sutton claims on the northeast side of the property. The Property contains numerous historical gold showings, as well as 18 historical pits and shafts.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. The forward-looking statements are based on certain key expectations and assumptions made by the Company. Although Warrior Gold believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Warrior Gold can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in the Company’s Management Discussion and Analysis of the financial condition and results of operations for the year ended March 31, 2020 and the first quarter ended June 30, 2020, which are available at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Warrior Gold undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005172/en/

Danièle Spethmann, P.Geo.

President & CEO

Warrior Gold Inc.

+1 647 344-3433

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Forest Products Natural Resources Mining/Minerals

MEDIA:

Posted on November 13, 2020 7:03 am

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

TORONTO–(BUSINESS WIRE)–
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the filing of its financial and operating results for the fiscal quarter ended September 30, 2020. The Company’s unaudited fiscal Q2 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR.

“We’ve made tremendous progress this quarter in preparing our lead drug for Phase III trials and partnering,” commented Dan Legault, Antibe’s CEO. “We are getting closer to the start of our Phase III program, with a total of eight Phase III-enabling studies now running in parallel. Additionally, the recent commercial data strengthens our position as we engage partners for the large markets. Finally, we are executing our capital markets strategy to increase institutional awareness and liquidity, highlighted by the recent graduation to the TSX. We look forward to providing a comprehensive corporate update in the coming weeks.”

Q2 2021 Highlights

• Announced robust secondary data from otenaproxesul’s Phase IIB dose-ranging, efficacy study, confirming the drug’s remarkable potency shown in earlier top-line results;
• Completed third party studies for the seven largest markets, framing an impressive commercial opportunity for otenaproxesul;
• Initiated two animal toxicology studies required for all companies by the US Food and Drug Administration to begin Phase III trials (six additional such studies have commenced in the current quarter);
• Launched pipeline expansion initiatives aimed at developing new intellectual property based on the Company’s hydrogen sulfide platform;
• Commenced a proprietary naming initiative for otenaproxesul with a leading global branding agency to determine the commercial brand/trademark;
• Engaged Stern IR, a premier investor relations agency for healthcare and biotechnology companies worldwide, to support Antibe’s institutional outreach in the US; and
• Completed the quarter with a cash balance of $22.5 million.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (“NSAIDs”) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with NSAIDs. Antibe’s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. Learn more at antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005162/en/

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-922-3460

[email protected]

Stern Investor Relations

Courtney Turiano

+1 212-362-1200

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo